Burton-on-Trent, UK – 11 January 2013 -- Clinigen Global Access Programs (Clinigen GAP), a division of Clinigen Group, has appointed Dominic Atkins as global business development director, effective immediately. In this senior commercial role reporting to Mark Corbett, Clinigen GAP’s vice-president, and based near Basel, Switzerland, Dominic will be responsible for identifying, assessing and developing new international business opportunities across the pharmaceutical product lifecycle.
In a career spanning almost 20 years, Dominic has developed extensive expertise in sales and marketing at national and international level. He also has experience in public policy/issues management, alliance management and business development.
Most recently, Dominic held a senior marketing position at Shire Human Genetics Therapies (Shire HGT), where he led and implemented marketing strategies throughout the EMEA region. He was previously director of business development and marketing at Santhera Pharmaceuticals and has also worked for Novartis and Wyeth (now Pfizer). He graduated from King’s College London with a degree in Chemistry and Management Studies.
Mark Corbett said: “We are delighted that Dominic has decided to join Clinigen GAP at such an exciting stage of our development. We are enjoying strong growth in our business and he is an excellent addition to our team. Dominic brings tremendous knowledge of the industry, as well as insights into our key strategic areas of specialty pharma and orphan drugs. Dominic also has direct experience of setting up and running early access programs and a strong network of contacts, which will bring a unique level of understanding to his interactions with our current and future pharmaceutical clients.”
About Clinigen GAP
Clinigen Group is a global specialty pharmaceutical products and services business headquartered in the UK, with offices in the US and Japan. Clinigen’s Global Access Programs division (Clinigen GAP) specializes in the consultancy, development, management and implementation of global access programs for biotechnology and pharmaceutical companies. Clinigen GAP provides clients with a fully outsourced solution for managing access to medicines which are otherwise unavailable in one or multiple markets.
Clinigen’s highly experienced team combines pharmaceutical and service expertise in the execution of innovative programs and is currently implementing programs providing medicines for thousands of patients globally.
For more information, visit www.clinigengroup.com
Pete Chan at Tudor Reilly
Office: +44 (0)207 034 3208
Mobile: +44 (0)7725 554 632